WHICH PATIENTS ARE ELIGIBLE FOR KYMRIAH?

Consider Kymriah for patients with relapsed or refractory DLBCL who have these characteristics Consider Kymriah for patients with relapsed or refractory DLBCL who have these characteristics
PARTNERSHIP DRIVES THE CREATION OF THIS INNOVATIVE, CUSTOMISED TREATMENT

Collaboration among physicians, Novartis, and the qualified Treatment Centre is crucial to delivering this personalised treatment

Select icon below to learn more about the KYMRIAH process

Patient
Identification

Flexible Collection and Cryopreservation
5. Post-Infusion
Monitoring

1. Flexible Collection
and Cryopreservation

Flexible Collection and Cryopreservation

2. Manufacturing

Proven and Reliable Manufacturing
Flexibility of Inpatient or Outpatient Infusion

4. Flexibility of Inpatient or
Outpatient Infusion

Specialized Shipping

3. Specialised Shipping

5. Post-Infusion
Monitoring
Flexible Collection and Cryopreservation

For full safety information, please see the Summary of Product Characteristics.

MANUFACTURING AN INDIVIDUALISED TREATMENT ON A GLOBAL SCALE
Proven Process on a Global Scale
Proven Process on a Global Scale2,3
KYMRIAH has been studied in global clinical trials in 11 countries and 27 sites across Europe, North America, Australia, and Asia. Due to the locations of these studies, KYMRIAH can be delivered on a global scale.
Adaptable Leukapheresis. Schedule collection as soon as a patient is identified, or at the time in the best interest of the patient
Adaptable Leukapheresis4
Schedule collection as soon as a patient is identified, or at a time in the best interest of the patient.
Proactively Collect cells, and store leukapheresis material for an extended period before manufacturing begins, if you decide that is the best treatment course for your patient
Extended Storage4
Proactively collect cells, and store leukapheresis material for an extended period (up to 30 months) before manufacturing begins, if you decide that is the best treatment course for your patient.
References:
  1. Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2021.
  2. Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Poster presented at: 59th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2017; Atlanta, GA. Abstract 577.
  3. Grupp SA, Maude SL, Rives S, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia. Presented at: 60th American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego, CA.
  4. Data on file. Novartis CTL019 Leukapheresis Reference Manual: leukapheresis collection. Novartis Pharmaceuticals Corp; June 2019.